Vertex sales jump but Orkambi misses estimates

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported 1Q16 revenues of $398.1 million, up from $138.5 million in 1Q15 but missing analysts' estimates of $439.4 million. The shortfall was attributable to

Read the full 284 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE